News

The hematologist/oncologist from Mayo Clinic discussed targeting HLA loss in solid tumors.

The LV-HSCGT therapy has demonstrated efficacy in preclinical studies in mouse models.

The gene therapy is currently under FDA review for the treatment of β-thalassemia across genotypes.

Dolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed the company’s collaboration with 2seventy bio to develop TCR T-cell therapies.

Results from the final analysis of the HOPE-B trial were presented at the 2022 EAHAD meeting.

Applied Genetic Technologies is also developing AGTC-401 and AGTC-402 for the treatment of achromatopsia.

The professor and head of coagulation disorders and Comprehensive Care Centre, University Hospital of Frankfurt, Germany, discussed results of the final analysis of the HOPE-B study.

Review top news and interview highlights from the week ending February 4, 2022.

No dose-limiting toxicities or treatment-emergent adverse events have been reported.

Carl June, MD, discussed the longest-term follow-up data on CAR T-cell therapy so far.

Kimmtrak is now the first approved therapy for unresectable or metastatic uveal melanoma.

The hold was prompted by the second development of a serious AE of thrombotic microangiopathy in a patient in the younger age group.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in gene and cell therapies.

SwanBio previously presented positive preclinical data at the ESGCT 2021 meeting.

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed the ATLAS-INH trial.

The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed challenges in hemophilia A and B.

The approval was based on findings from the phase 2 KarMMa trial and the phase 1 Study CRB-401 trial.

The positive news is countered by a report of a patient death in Taysha’s gene therapy program for GM2 gangliosidosis.

The FDA has approved the prescribing label update based on data from a new safety management cohort of the phase 1/2 ZUMA-1 trial.

The clinical trial of 4D-150 expects to enroll around 60 participants with wet AMD.

The director of the Melanoma Program at Cedars-Sinai Medical Center discussed the efficacy of TIL therapy following immunotherapy in advanced melanoma.

Both the Sirius and Celeste phase 2/3 trials are evaluating QR-421a.

Experts discussed the ZUMA-2 clinical trial of brexucabtagene autoleucel.

Review top news and interview highlights from the week ending January 28, 2022.

Exciting new therapies are on the horizon for inherited retinal disease. We’ve compiled a quick snapshot of promising investigative therapies.

The latest hold on MB-207 follows a similar hold on another XSCID therapy, MB-107.

The director of the Melanoma Program at Cedars-Sinai Medical Center discussed evaluation criteria for TIL therapy in melanoma.

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from both the CARTITUDE-1 and CARTITUDE-2 studies.